IP Library Granted Patent US 9,999,610
Granted Patent B2
US 9,999,610 · App. 15/083,513 · Granted Jun 19, 2018

Pharmaceutical use of 3-benzylsulfonylpropionitrile

Inventors: Joseph P. St. Laurent (Lakeville, MA); Gerald S. Jones (Norwood, MA); David M. Bresse (Middleboro, MA); Scott A. Goodrich (Stoughton, MA)
Assignee: Olatec Therapeutics LLC
A61K31/277A61K9/0014
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,999,610
App. No.
15/083,513
Granted
Jun 19, 2018
Kind
B2
Abstract

The present invention is directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 3-benzylsulfonylpropionitrile, in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred route of administration.

Claims (3)

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound 3-benzylsulfonylpropionitrile, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethyl ether, caprylic/capric triglyceride, octisalate, silicone fluid, squalene, and sunflower oil.

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound 3-benzylsulfonylpropionitrile, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethyl ether.

3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound 3-benzylsulfonylpropionitrile, or a pharmaceutically acceptable salt thereof, wherein the compound has at least 90% (w/w) purity, and the pharmaceutically acceptable carrier is an excipient selected from the group consisting of: carboxymethylcellulose, cellulose, ethylcellulose, hydroxypropylmethylcellulose, methylcellulose, karaya gum, starch, tragacanth gum, gelatin, magnesium stearate, titanium dioxide , poly(acrylic acid), polyvinylpyrrolidone, colloidal silicon dioxide, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and any combination thereof.

Assignments (1)
CHANGE OF NAME Recorded Nov 7, 2023
From: OLATEC THERAPEUTICS LLC
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 065489/0809 →
Continuity (4)
Continuation In Part PCTUS2014058347 · Sep 30, 2014
Provisional Application 61885428 · Oct 1, 2013
Provisional Application 62140402 · Mar 30, 2015
Related Publication 20160206589A1 · Jul 21, 2016